Other Clinical Trial - cAMP Signaling & Muscle Adaptations

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

The role of cAMP signaling mediated by beta2-adrenergic stimulation with agonists has been well-studied in skeletal muscles of animals. Studies in humans are scant and the scope of the present study is thus to investigate the role of cAMP signaling by beta2-adrenergic stimulation for muscle adaptations in humans.

See also
	Status	Clinical Trial	Phase
	Completed	`NCT02551276` - Chronic Beta2-adrenergic Stimulation and Cardiac and Skeletal Muscle Hypertrophy	N/A

NCT number	NCT02557581
Study type	Interventional
Source	University of Copenhagen
Contact	Morten Hostrup, PhD
Phone	+4524474785
Email	mortenhostrup@gmail.com
Status	Recruiting
Phase	N/A
Start date	July 2015
Completion date	October 2017

cAMP Signaling and Muscle Adaptations

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms